immune system
• DSS-treated mice exhibit more rapid colitis onset and increased colitis score compared with wild-type mice
• DSS-treated mice exhibit increased susceptibility to chronic colitis with more exaggerated weight loss, impaired crypt regeneration and resolution of colonic inflammation compared with wild-type mice
• however, severity of colitis is normal
|
• in colonic lamina prioria, especially activated dendritic cells and activated CD103+ gut-resident dendritic cells
• however, spleen numbers are normal
|
• to oral ovalbumin with broken oral tolerance
|
• impaired oral tolerance to ovalbumin
|
digestive/alimentary system
N |
• mice exhibit normal intestinal epithelial cell lineage differentiation and proliferation in addition to an extremely mild, age-progressive colitis without steady-state colitis
|
• impaired intestinal barrier functions after DSS treatment
• however, untreated mice exhibit normal intestinal barrier function
|
• DSS-treated mice exhibit more rapid colitis onset and increased colitis score compared with wild-type mice
• DSS-treated mice exhibit increased susceptibility to chronic colitis with more exaggerated weight loss, impaired crypt regeneration and resolution of colonic inflammation compared with wild-type mice
• however, severity of colitis is normal
|
neoplasm
• AOM/DSS-treated mice exhibit increased colon tumor burden compared with wild-type mice
• however, mice are not predisposed to sporadic colorectal cancer
|
growth/size/body
• in mice chronically-treated with DSS
|
homeostasis/metabolism
• AOM/DSS-treated mice exhibit increased colon tumor burden compared with wild-type mice
• however, mice are not predisposed to sporadic colorectal cancer
|
hematopoietic system
• in colonic lamina prioria, especially activated dendritic cells and activated CD103+ gut-resident dendritic cells
• however, spleen numbers are normal
|